HAVANA (Reuters) -Cuba's Soberana 2 vaccine candidate has shown 62% efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma said on Saturday, citing preliminary data from late phase trials.
Cuba, whose biotech sector https://www.reuters.com/article/uk-health-coronavirus-vaccine-cuba-focus-idUKKBN27S1OZ has exported vaccines for decades, has five vaccine candidates in clinical trials, of which two - Soberana 2 and Abdala - are in late phase trials.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!